Jianye Yuan1, Susan S Baker, Wensheng Liu, Razan Alkhouri, Robert D Baker, Jianqun Xie, Guang Ji, Lixin Zhu. 1. Digestive Diseases and Nutrition Center, Department of Pediatrics, The State University of New York at Buffalo, Buffalo, New York, USA; Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Abstract
BACKGROUND AND AIM: Nonalcoholic steatohepatitis (NASH), the severe form of nonalcoholic fatty liver disease, is a serious liver complication associated with obesity. Several studies suggest that endotoxemia is associated with nonalcoholic fatty liver disease and NASH. We aimed to study the correlation of gut microbiome composition and the incidence of endotoxemia in obese patients and NASH patients in comparison with normal controls. METHODS: The abundance of Gram-negative bacteria in the gut microbiomes of normal controls, obese patients with normal liver, and biopsy-proven NASH patients were assessed using 16S rRNA pyrosequencing data. Serum endotoxin was determined by endpoint limulus amebocyte lysate assay. RESULTS: Higher abundance of Gram-negative bacteria in gut microbiome was observed in obese and NASH patients in comparison with normal controls, but no difference was detected between obese and NASH patients. Serum endotoxin is higher in the NASH group than the normal controls. In addition, the obese and NASH patients had a higher incidence of endotoxemia compared with normal controls. However, Spearman's test found no correlation between the abundance of Gram-negative bacteria and serum endotoxin levels. The majority of the NASH patients and the obese patients had low serum endotoxin level. Among NASH patients, serum endotoxin is not correlated with disease severity. CONCLUSIONS: Our data suggest that the gut microbiome composition does not contribute to the incidence of endotoxemia in NASH, and endotoxemia is not required in the pathogenesis of NASH. Our observations highlight the current concept that multiple factors contribute to the development of NASH.
BACKGROUND AND AIM: Nonalcoholic steatohepatitis (NASH), the severe form of nonalcoholic fatty liver disease, is a serious liver complication associated with obesity. Several studies suggest that endotoxemia is associated with nonalcoholic fatty liver disease and NASH. We aimed to study the correlation of gut microbiome composition and the incidence of endotoxemia in obesepatients and NASH patients in comparison with normal controls. METHODS: The abundance of Gram-negative bacteria in the gut microbiomes of normal controls, obesepatients with normal liver, and biopsy-proven NASH patients were assessed using 16S rRNA pyrosequencing data. Serum endotoxin was determined by endpoint limulus amebocyte lysate assay. RESULTS: Higher abundance of Gram-negative bacteria in gut microbiome was observed in obese and NASH patients in comparison with normal controls, but no difference was detected between obese and NASH patients. Serum endotoxin is higher in the NASH group than the normal controls. In addition, the obese and NASH patients had a higher incidence of endotoxemia compared with normal controls. However, Spearman's test found no correlation between the abundance of Gram-negative bacteria and serum endotoxin levels. The majority of the NASH patients and the obesepatients had low serum endotoxin level. Among NASH patients, serum endotoxin is not correlated with disease severity. CONCLUSIONS: Our data suggest that the gut microbiome composition does not contribute to the incidence of endotoxemia in NASH, and endotoxemia is not required in the pathogenesis of NASH. Our observations highlight the current concept that multiple factors contribute to the development of NASH.
Authors: Ming Song; Xiaohong Li; Xiang Zhang; Hongxue Shi; Miriam B Vos; Xiaoli Wei; Yuhua Wang; Hong Gao; Eric C Rouchka; Xinmin Yin; Zhanxiang Zhou; Russell A Prough; Matthew C Cave; Craig J McClain Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-10-12 Impact factor: 4.052
Authors: Wei Perng; Jacob E Friedman; Rachel C Janssen; Deborah H Glueck; Dana Dabelea Journal: J Clin Endocrinol Metab Date: 2022-06-16 Impact factor: 6.134